Leo Pharma and 4SC Discovery announce skin disease alliance

Leo Pharma will be collaborating with 4SC Discovery to research, develop and commercialise an oral treatment for inflammatory skin diseases such as psoriasis.

Under the terms of the alliance, Leo Pharma will provide 4SC Discovery with research funding and milestone fees in exchange for global rights to market the drug as a therapy for chronic skin conditions.

Although the compound is currently in the early stages of development, it is thought that it could potentially significantly reduce if not entirely eradicate symptoms of psoriasis, based on results from preclinical studies.

This deal comes as part of Leo Pharma's growth strategy of actively pursuing new opportunities to expand its pipeline with innovative therapies.

Kim Kjoeller, senior vice-president for global development at Leo Pharma, said: "This latest deal is the perfect example of our commitment to meeting patient needs with breakthrough novel therapies."

Leo Pharma was originally founded in 1908 and now manufactures and markets drugs to dermatologic and thrombotic patients in more than 100 countries globally.